权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

“Pharmacologic targeting of NR4A1 and NR4A2 to activate glioblastoma treatment response”

– NR4A1 和 NR4A2 的药理学靶向激活胶质母细胞瘤治疗反应 –

基本信息

批准号：
10744524
负责人：
Andrei M Mikheev
金额：
$ 50.34万
依托单位：
METHODIST HOSPITAL RESEARCH INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-19 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10744524
关键词：
Adoptive Transfer Adult Automobile Driving Bioinformatics Biological Assay Biology Cancer Model Carcinoma Cell Line Cell Proliferation Cell physiology Cells Cessation of life Clinical Trials Data Drug Kinetics Exhibits Future Gene Expression Genes Genetic Glioblastoma Goals Human IL8 gene Immune Immune Evasion Immune checkpoint inhibitor Immune response Immunooncology Immunosuppression Immunotherapy Indoles Infiltration Invaded Lead Ligands Macrophage Malignant - descriptor Malignant Neoplasms Malignant neoplasm of brain Measures Mediating Mesenchymal Mesenchymal Cell Neoplasm Modeling Molecular Mus Myeloid Cells Myeloid-derived suppressor cells NR4A1 gene NR4A2 gene Nuclear Orphan Receptor Orphan Nuclear Receptor Gene Outcome Patients Pharmaceutical Chemistry Pharmaceutical Preparations Phenotype Pre-Clinical Model Preclinical Testing Production Proliferating Property Radiation therapy Receptor Inhibition Regulation Regulatory T-Lymphocyte Resistance Role Series Signal Transduction T cell differentiation T-Lymphocyte TWIST1 gene Testing Therapeutic Toxic effect Tumorigenicity antagonist anti-cancer bioinformatics tool candidate identification checkpoint therapy chemoradiation conventional therapy cytokine cytotoxicity exhaust exhaustion improved in vivo in vivo evaluation knock-down loss of function migration multidisciplinary neoplastic cell neuro-oncology novel novel strategies novel therapeutics pharmacologic pre-clinical programmed cell death ligand 1 programs radiation resistance receptor receptor expression response self-renewal single-cell RNA sequencing standard of care stem cell self renewal stemness temozolomide therapy resistant treatment response tumor tumor growth tumor microenvironment tumor-immune system interactions

项目摘要

Resistance to standard of care (SOC) temozolomide (TMZ) and radiation treatment (XRT) limits survival of the most common adult brain cancer, glioblastoma (GBM), to 12-18 months. Despite promising results in other cancers, robust immunosuppression in GBM has also limited the responses to immune checkpoint inhibitors (ICIs). Reciprocal interactions in the GBM tumor microenvironment (TME) between mesenchymal changes and immunosuppression enhance resistance to chemoradiation and immunotherapy, respectively. Therefore, a compelling therapeutic strategy for GBM is to concurrently reprogram the mesenchymal and immune suppressive TMEs and potentiate ICI and SOC therapy. The NR4A1 and NR4A2 orphan nuclear receptors are compelling targets to achieve this goal. We synthesized a series of novel bis-indole–derived ligands (CDIMs) with potent dual antagonism of NR4A1 and NR4A2 and negligible in vivo toxicity, of which six demonstrated nM range KDs for both receptors. Genetic based NR4A 1 and 2 loss of function strongly activates anti-cancer immune responses by reversing T-cell exhaustion which underlies poor ICI responses in GBM. In addition, NR4A1/2 promote EMT in other cancers which contributes to chemoradiation resistance. Finally, high levels of NR4A1/2 expression in GBM are strongly associated with decreased patient survival after conventional treatments. Therefore, we propose to test the hypothesis that CDIM inhibition of NR4A1/2 reprograms the GBM TME and potentiates ICI and TMZ/XRT responses. Further NR4A1/2 upregulates PD-L1 and TWISt1, key regulators of GBM immune suppression and mesenchymal phenotypes, respectively. Preliminary studies demonstrated that CDIMs inhibit PD-L1 and TWIST1 expression, reverse immune suppressive myeloid and T cell phenotypes and prolong survival of experimental GBMs. We will test our hypothesis by i) identifying lead dual NR4A1/2 CDIM compounds based on inhibition of malignant and mesenchymal GBM cell properties (proliferation, self-renewal, invasion) and reversal of dysfunctional T cell phenotypes in vivo (Aim 1), ii) establishing the functional impact of NR4A1/2 CDIMs to reprogram the immune suppressive and mesenchymal TME (Aim 2) and iii) quantifying the effects of NR4A1/2 CDIMs to potentiate ICI and SOC responses in mouse GBM syngeneic models and define the role of PD-L1 and TWIST1 in their mechanisms of action (Aim 3). Quantification of potency, pharmacokinetics and preclinical anti-tumor activity alone and in combination with to standard of care TMZ-XRT and ICIs is expected to identify candidate CDIMs for consideration in future clinical trials. Through application of powerful bioinformatic tools that model the cancer TME through integration of scRNAseq, cyTOF and IMC data, these studies are expected to shed new light on novel mechanisms by which mesenchymal and immune suppressive TMEs interact to coordinately drive treatment resistance in GBM through NR4A1/2. To achieve our goals, we assembled a unique multidisciplinary team with expertise in medicinal chemistry, neuro-oncology, GBM biology and preclinical modeling, and immuno-oncology.

对标准治疗（SOC）替莫唑胺（TMZ）和放射治疗（XRT）的耐药性限制了患者的生存